Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 6/20 | 0.32 |
| ▸ | TLR2 | O60603 | 2/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.32 |
| ▸ | SCN2B | O60939 | 1/20 | 0.31 |
| ▸ | SCN1A | P35498 | 1/20 | 0.31 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | VNN1 | O95497 | 1/20 | 0.30 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12378399 | 0.90 | LIPG (0.36) | LIPGMEN1KMT2ACNR2TLR2 | |
| SCHEMBL13623970 | 0.87 | PTGER4 (0.32) | LIPGPTGER4 | |
| SCHEMBL12378352 | 0.87 | CSNK1D (0.33) | LIPGMEN1KMT2ACNR2TLR2 | |
| SCHEMBL12378421 | 0.86 | GPR52 (0.39) | LIPGMEN1KMT2ATLR2L3MBTL1 | |
| SCHEMBL13623961 | 0.86 | PLA2G2A (0.36) | LIPGMEN1KMT2ACNR2TLR2 | |
| SCHEMBL13624013 | 0.86 | GRM2 (0.37) | LIPGTLR2CSNK1D | |
| SCHEMBL12378401 | 0.86 | MEN1 (0.36) | LIPGMEN1KMT2ACNR2TLR2 | |
| SCHEMBL13624003 | 0.85 | PTGER4 (0.33) | LIPGNTRK1VNN1PTGER4 | |
| SCHEMBL13624054 | 0.85 | SCN9A (0.38) | LIPGKMT2ACNR2SCN9APTGER4 | |
| SCHEMBL13623964 | 0.85 | CSNK1D (0.32) | LIPGMEN1KMT2ACNR2TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291921-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291921-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291921-A1 | INTEGRASE INHIBITORS | TYMP, DNTT, PAICS | LIPG 2233/4885MEN1 4674/4885KMT2A 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.